BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 20711715)

  • 1. Sensor-augmented pump therapy from the diagnosis of childhood type 1 diabetes: results of the Paediatric Onset Study (ONSET) after 12 months of treatment.
    Kordonouri O; Pankowska E; Rami B; Kapellen T; Coutant R; Hartmann R; Lange K; Knip M; Danne T
    Diabetologia; 2010 Dec; 53(12):2487-95. PubMed ID: 20711715
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glycaemic impact of patient-led use of sensor-guided pump therapy in type 1 diabetes: a randomised controlled trial.
    O'Connell MA; Donath S; O'Neal DN; Colman PG; Ambler GR; Jones TW; Davis EA; Cameron FJ
    Diabetologia; 2009 Jul; 52(7):1250-7. PubMed ID: 19396424
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The use and efficacy of continuous glucose monitoring in type 1 diabetes treated with insulin pump therapy: a randomised controlled trial.
    Battelino T; Conget I; Olsen B; Schütz-Fuhrmann I; Hommel E; Hoogma R; Schierloh U; Sulli N; Bolinder J;
    Diabetologia; 2012 Dec; 55(12):3155-62. PubMed ID: 22965294
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of suspend-before-low insulin pump technology in hypoglycaemia-prone adults with type 1 diabetes (SMILE): an open-label randomised controlled trial.
    Bosi E; Choudhary P; de Valk HW; Lablanche S; Castañeda J; de Portu S; Da Silva J; Ré R; Vorrink-de Groot L; Shin J; Kaufman FR; Cohen O;
    Lancet Diabetes Endocrinol; 2019 Jun; 7(6):462-472. PubMed ID: 31047902
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of predicted low suspend pump treatment on improving glycaemic control and quality of sleep in children with type 1 diabetes and their caregivers: the QUEST randomized crossover study.
    Schierloh U; Aguayo GA; Fichelle M; De Melo Dias C; Celebic A; Vaillant M; Barnard K; Cohen O; de Beaufort C
    Trials; 2018 Dec; 19(1):665. PubMed ID: 30509293
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of sensor-integrated pump therapy to reduce hypoglycaemia in people with Type 1 diabetes: a real-world study in the UK.
    Choudhary P; de Portu S; Arrieta A; Castañeda J; Campbell FM
    Diabet Med; 2019 Sep; 36(9):1100-1108. PubMed ID: 31134668
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of sensor-augmented insulin pump therapy and automated insulin suspension vs standard insulin pump therapy on hypoglycemia in patients with type 1 diabetes: a randomized clinical trial.
    Ly TT; Nicholas JA; Retterath A; Lim EM; Davis EA; Jones TW
    JAMA; 2013 Sep; 310(12):1240-7. PubMed ID: 24065010
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of dual-hormone artificial pancreas, single-hormone artificial pancreas, and conventional insulin pump therapy for glycaemic control in patients with type 1 diabetes: an open-label randomised controlled crossover trial.
    Haidar A; Legault L; Messier V; Mitre TM; Leroux C; Rabasa-Lhoret R
    Lancet Diabetes Endocrinol; 2015 Jan; 3(1):17-26. PubMed ID: 25434967
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sensor augmented pump therapy from onset of type 1 diabetes: late follow-up results of the Pediatric Onset Study.
    Kordonouri O; Hartmann R; Pankowska E; Rami B; Kapellen T; Coutant R; Lange K; Danne T
    Pediatr Diabetes; 2012 Nov; 13(7):515-8. PubMed ID: 22487079
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Day and night glycaemic control with a bionic pancreas versus conventional insulin pump therapy in preadolescent children with type 1 diabetes: a randomised crossover trial.
    Russell SJ; Hillard MA; Balliro C; Magyar KL; Selagamsetty R; Sinha M; Grennan K; Mondesir D; Ekhlaspour L; Zheng H; Damiano ER; El-Khatib FH
    Lancet Diabetes Endocrinol; 2016 Mar; 4(3):233-243. PubMed ID: 26850709
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Continuous subcutaneous insulin infusion versus multiple daily injection regimens in children and young people at diagnosis of type 1 diabetes: pragmatic randomised controlled trial and economic evaluation.
    Blair JC; McKay A; Ridyard C; Thornborough K; Bedson E; Peak M; Didi M; Annan F; Gregory JW; Hughes DA; Gamble C;
    BMJ; 2019 Apr; 365():l1226. PubMed ID: 30944112
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of frequency of sensor use on glycaemic control in individuals on sensor-augmented pump therapy with and without Predictive Low Glucose Management System.
    Abraham MB; Smith GJ; Nicholas JA; Fairchild JM; King BR; Ambler GR; Cameron FJ; Davis EA; Jones TW;
    Diabetes Res Clin Pract; 2020 Jan; 159():107989. PubMed ID: 31866529
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Health-economic analysis of real-time continuous glucose monitoring in people with Type 1 diabetes.
    Roze S; Saunders R; Brandt AS; de Portu S; Papo NL; Jendle J
    Diabet Med; 2015 May; 32(5):618-26. PubMed ID: 25483869
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diabetes technology and treatments in the paediatric age group.
    Shalitin S; Peter Chase H
    Int J Clin Pract Suppl; 2011 Feb; (170):76-82. PubMed ID: 21323816
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Routine use of continuous glucose monitoring in 10 501 people with diabetes mellitus.
    Battelino T; Liabat S; Veeze HJ; Castañeda J; Arrieta A; Cohen O
    Diabet Med; 2015 Dec; 32(12):1568-74. PubMed ID: 26042926
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized trial of a dual-hormone artificial pancreas with dosing adjustment during exercise compared with no adjustment and sensor-augmented pump therapy.
    Jacobs PG; El Youssef J; Reddy R; Resalat N; Branigan D; Condon J; Preiser N; Ramsey K; Jones M; Edwards C; Kuehl K; Leitschuh J; Rajhbeharrysingh U; Castle JR
    Diabetes Obes Metab; 2016 Nov; 18(11):1110-1119. PubMed ID: 27333970
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Faster insulin action is associated with improved glycaemic outcomes during closed-loop insulin delivery and sensor-augmented pump therapy in adults with type 1 diabetes.
    Ruan Y; Thabit H; Leelarathna L; Hartnell S; Wilinska ME; Tauschmann M; Dellweg S; Benesch C; Mader JK; Holzer M; Kojzar H; Evans ML; Pieber TR; Arnolds S; Hovorka R;
    Diabetes Obes Metab; 2017 Oct; 19(10):1485-1489. PubMed ID: 28371223
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Home use of a bihormonal bionic pancreas versus insulin pump therapy in adults with type 1 diabetes: a multicentre randomised crossover trial.
    El-Khatib FH; Balliro C; Hillard MA; Magyar KL; Ekhlaspour L; Sinha M; Mondesir D; Esmaeili A; Hartigan C; Thompson MJ; Malkani S; Lock JP; Harlan DM; Clinton P; Frank E; Wilson DM; DeSalvo D; Norlander L; Ly T; Buckingham BA; Diner J; Dezube M; Young LA; Goley A; Kirkman MS; Buse JB; Zheng H; Selagamsetty RR; Damiano ER; Russell SJ
    Lancet; 2017 Jan; 389(10067):369-380. PubMed ID: 28007348
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessing the efficacy, safety and utility of closed-loop insulin delivery compared with sensor-augmented pump therapy in very young children with type 1 diabetes (KidsAP02 study): an open-label, multicentre, multinational, randomised cross-over study protocol.
    Fuchs J; Allen JM; Boughton CK; Wilinska ME; Thankamony A; de Beaufort C; Campbell F; Yong J; Froehlich-Reiterer E; Mader JK; Hofer SE; Kapellen TM; Rami-Merhar B; Tauschmann M; Hood K; Kimbell B; Lawton J; Roze S; Sibayan J; Cohen N; Hovorka R;
    BMJ Open; 2021 Feb; 11(2):e042790. PubMed ID: 33579766
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.